Alcon/$ALC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Primary listing
NYSE
Employees
25,000
Headquarters
Geneva, Switzerland
Website
Alcon Metrics
BasicAdvanced
$37B
34.90
$2.16
0.69
$0.22
0.29%
Price and volume
Market cap
$37B
Beta
0.69
52-week high
$99.20
52-week low
$73.22
Average daily volume
2M
Dividend rate
$0.22
Financial strength
Current ratio
2.601
Quick ratio
1.413
Long term debt to equity
23.064
Total debt to equity
23.773
Dividend payout ratio (TTM)
15.47%
Interest coverage (TTM)
6.54%
Profitability
EBITDA (TTM)
2,342
Gross margin (TTM)
55.56%
Net profit margin (TTM)
10.70%
Operating margin (TTM)
12.86%
Effective tax rate (TTM)
14.43%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.64%
Return on equity (TTM)
4.98%
Valuation
Price to earnings (TTM)
34.897
Price to revenue (TTM)
3.721
Price to book
1.35
Price to tangible book (TTM)
8.02
Price to free cash flow (TTM)
26.364
Free cash flow yield (TTM)
3.79%
Free cash flow per share (TTM)
2.859
Dividend yield (TTM)
0.29%
Forward dividend yield
0.29%
Growth
Revenue change (TTM)
4.04%
Earnings per share change (TTM)
-2.69%
3-year revenue growth (CAGR)
5.01%
3-year earnings per share growth (CAGR)
32.89%
3-year dividend per share growth (CAGR)
12.09%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Bulls say / Bears say
The FDA approved Alcon’s first-in-class dry eye treatment Tryptyr on May 28, 2025, addressing an estimated 38 million U.S. sufferers—fewer than 10% of whom receive prescription therapies—expanding Alcon’s ophthalmic pipeline (Reuters)
In Q2 2025, Alcon reported net sales of $2.6 billion, up 4% year-over-year; Vision Care sales grew 6% and contact lens sales jumped 9% (7% constant currency) on strong product innovation and price increases (Business Wire)
Alcon agreed to acquire STAAR Surgical for $1.5 billion on August 5, 2025, adding the EVO ICL portfolio for high myopia—addressing a market of nearly 500 million high myopes globally—and diversifying its surgical vision correction offerings (Business Wire)
Surgical implantables net sales declined 2% year-over-year and equipment/other sales dropped 5% in Q2 2025, signaling softness and competitive pressures in its high-margin Surgical segment (Business Wire)
Alcon trimmed its full-year 2025 net sales guidance to $10.3 billion–$10.4 billion from $10.4 billion–$10.5 billion set in May, reflecting softer market conditions and tariff-related headwinds (Vision Monday)
In its August outlook, Alcon cut core operating margin guidance by roughly 100 basis points to 19.5%–20.5% from the prior 20%–21% range, highlighting ongoing margin pressure from tariffs and R&D investments (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
Business Wire2 hours ago
Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
Business Wire2 days ago
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
Business Wire2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alcon stock?
Alcon (ALC) has a market cap of $37B as of October 08, 2025.
What is the P/E ratio for Alcon stock?
The price to earnings (P/E) ratio for Alcon (ALC) stock is 34.9 as of October 08, 2025.
Does Alcon stock pay dividends?
Yes, the Alcon (ALC) stock pays dividends to shareholders. As of October 08, 2025, the dividend rate is $0.21783 and the yield is 0.29%. Alcon has a payout ratio of 15.47% on a trailing twelve-month basis.
When is the next Alcon dividend payment date?
The next Alcon (ALC) dividend payment date is unconfirmed.
What is the beta indicator for Alcon?
Alcon (ALC) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.